A reduction of 543 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
The number of people who have recuperated from the disease surged to 1,06,67,741 which translates to a national COVID-19 recovery rate of 97.30 per cent and the case fatality rate stands at 1.42 per cent.
The number of people who have recuperated from the disease surged to 1,06,33, 025 which translates to a national COVID-19 recovery rate of 97.32 per cent, while the COVID-19 case fatality rate stands at 1.43 per cent.
The number of people who have recuperated from the disease has surged to 1,05,73,372, which translates to a national COVID-19 recovery rate of 97.26 per cent, while the case fatality rate stands at 1.43 per cent.
A total of 9,110 new infections were reported in a span of 24 hours, while the death toll increased to 1,55,158 with 78 daily new fatalities, the data updated at 8 am showed.
Each vaccination session will cater to a maximum of 100 beneficiaries and the Union Health Ministry has advised states not to organise 'unreasonable numbers of vaccination per site per day'.
The active cases comprise 0.05 per cent of the total infections, while the national COVID-19 recovery rate has been recorded at 98.75 per cent, the ministry said.
The COVID-19 case fatality rate due to the coronavirus infection was recorded at 1.59 per cent.
The active cases comprise 0.26 per cent of the total infections, while the national COVID-19 recovery rate was recorded at 98.53 per cent, the ministry said.
The officials of Indian Council of Medical Research (ICMR) also said there are now 1,065 testing labs in the country -- 768 in the public sector and 297 in private.
The death toll climbed to 5,25,242 with 19 new fatalities, the data updated at 8 am stated.
The minister said whatever is being done now are "the perfect scientific advice".
The Indian Council of Medical Research's national task force for COVID-19 has decided against including antiviral drug Molnupiravir in the clinical management protocol for COVID-19 as of now, official sources said on Tuesday.
The number of people who have recuperated from the disease surged to 1,00,92,909, pushing the national COVID-19 recovery rate to 96.43 per cent, while the case fatality rate was recorded at 1.44 per cent.
Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.
The death toll climbed to 5,24,974 with 20 more fatalities, the data updated at 8 am stated.
The recovery rate has increased to 76.62 per cent, while the fatality rate has declined to 1.78 per cent.
The total coronavirus cases mounted to 63,12,584, while the death toll climbed to 98,678 with the virus claiming 1,181 lives in a span of 24 hours, the data updated at 8 am showed.
An increase of 2,613 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
The death toll from the pathogen climbed to 95,542 with 1,039 more deaths. There are 9,62,640 active cases of the coronavirus disease (COVID-19), comprising 15.85 per cent of the caseload, according to the ministry data.
An increase of 3,482 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
The COVID-19 active caseload remained below 4 lakh for the seventh consecutive day.
The case fatality rate has dropped 2.01 per cent, according to ministry data.
The COVID-19 case fatality rate due to the coronavirus infection has further dropped to 1.66 per cent.
The country had recorded 355 deaths on December 17 last year.
The COVID-19 case fatality rate stands at 1.45 per cent.
Active case tally increased by 3,769 and now comprise 0.08 per cent of the total infections.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The daily COVID-19 cases are being recorded at less than one lakh for the last six consecutive days.
As many as 47,905 new infections were recorded in a span of 24 hours on November 12 last year, it said.
There are 8,15,538 active cases of coronavirus infection in the country.
One of the biggest lessons for cities fighting the Covid-19 pandemic has been the criticality of access to data. Mumbai, which has shown significant success in managing the second wave of the pandemic, is a case in point, reports Shivani Shinde.
India saw a single day rise of 58,077 coronavirus infections, which took the tally of cases to 4,25,36,137, while the active cases have declined to 6,97,802, according to Union health ministry data updated on Friday.
The most important finding of the study was that the Spike-protein neutralising antibodies found in the mixed vaccine groups were significantly higher than the same-vaccine groups, D Nageshwar Reddy, Chairman of AIG Hospitals said.
Registering an increase for the 11th day in a row, the total active caseload has increased to 3,09,087, which now comprises 2.66 per cent of the total infections, while the recovery rate has further dropped to 95.96 per cent, the data stated.
While Maharashtra Home Minister Anil Deshmukh warned the yoga guru that the state government won't allow the sale of 'spurious' medicines, Rajasthan Health Minister Raghu Sharma also said that the state government will not allow the sale of Patanjali's Ayurvedic formulation.
The death toll climbed to 5,24,636 with six fatalities, the data updated at 8 am stated.
'Delta continues to be the dominant lineage for new cases across all parts of India in recent samples and remains the most rapidly rising lineage globally that is responsible for multiple outbreaks, including across Southeast Asia, which shows the fastest growth in new cases globally,' the INSACOG said.
COVID-19 cases in the country jumped from 10 lakh to 20 lakh in 21 days, while it had taken 59 days for the cases to cross the 10 lakh-mark.
The active cases comprise 0.04 per cent of the total infections, while the national COVID-19 recovery rate was 98.74 per cent, the ministry said.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances